Analysis of comorbid conditions and tolerability of treatment with genetically engineered biological drugs and methotrexate in patients with psoriasis
- Authors: Zhufina S.E1, Fomin K.A1, Svechnikova E.V.1,2
-
Affiliations:
- Polyclinic № 1, Administrative Department of the President of the Russian Federation
- Novosibirsk State Medical University
- Issue: Vol 28, No 8 (2021)
- Pages: 20-26
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313199
- DOI: https://doi.org/10.18565/pharmateca.2021.8.20-26
- ID: 313199
Cite item
Open Access
Access granted
Abstract
The article presents the modern data on the pathogenesis of psoriasis, the mechanisms and pathogenesis of the development of comorbid diseases. The analysis of case histories for comorbid conditions of patients receiving therapy with secukinumab and methotrexate, assessment of the tolerability of therapy and its effect on laboratory parameters were carried out.
Full Text
About the authors
S. E Zhufina
Polyclinic № 1, Administrative Department of the President of the Russian FederationMoscow, Russia
K. A Fomin
Polyclinic № 1, Administrative Department of the President of the Russian FederationMoscow, Russia
Elena V. Svechnikova
Polyclinic № 1, Administrative Department of the President of the Russian Federation; Novosibirsk State Medical University
Email: elene-elene@bk.ru
Dr. Sci. (Med.), Dermatovenerologist, Head of the Department of Dermatovenereology and Cosmetology Moscow, Russia
References
- National Psoriasis Foundation Statistics, 2018. URL: https://www.psoriasis.org/content/statistics (last accessed: 21 September 2018).
- Александрова Г.А., Голубев Н.А., Тюрина Е.М. и др. Заболеваемость всего населения России в 2019 г Статистические материалы. Часть I. М., 2020. [Aleksandrova G.A., Golubev N.A., Tyurina E.M., et al. The incidence of the entire population of Russia in 2019. Statistical materials. Part I. M., 2020. (In Russ.)].
- Александрова Г.А., Голубев Н.А., Тюрина Е.М. и др. Заболеваемость всего населения России в 2019 году. Статистические материалы. Часть II. М., 2020. [Aleksandrova G.A., Golubev N.A., Tyurina E.M., et al. The incidence of the entire population of Russia in 2019. Statistical materials. Part II. M., 2020. (In Russ.).].
- Takeshita J., Grewal S., Langan S.M., et al. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017;76: 393-403. doi: 10.1016/j.jaad.2016.07.065.
- Хисматуллина З.Р, Аминева А.М., Курочкин Д.П. и др. Псориаз, псориатический артрит, метаболические нарушения и сердечно-сосудистые заболевания. Что общего? Клиническая дерматология и венерология. 2020;19(2):139-47.
- Boehncke W.-H. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579.
- Jose Laerte Boechat. Psoriatic March, Skin Inflammation and Cardiovascular Events - Two Plaques for one Syndrome. Int J Cardiovasc Sci. 2020:33(2):109-11. Doi:10.36660/ ijcs.20200021.
- Holm J.G., Simon F. Thomsen Type 2 diabetes and psoriasis: links and risks. Psoriasis (Auckl). 2019;9:1-6. doi: 10.2147/PTT.S159163.
- Rungapiromnan W., Mason K.J., Lunt M., Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study J Eur Acad Dermatol Venereol 2020;34(4):769-778. doi: 10.1111/jdv.16018.
- Krueger J.G., Patrick M. Brunner Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities Exp Dermatol. 2018;27:115-23. doi: 10.1111/exd.13467.
- Puig L. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2018;19:58. doi: 10.3390/ijms19010058.
- Lockshin B., Balagula Y., Merola J.F. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;345-doi: 10.1016/j.jaad.2018.02.040.
- Elnabawi Y.A., Dey A.K. Aditya Goyal Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019;115:721-28. doi: 10.1093/cvr/cvz009.
- Ryan C., Kirby B. Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities. Dermatol Clin. 2015;33:41-55. doi: 10.1016/j.det.2014.09.004.
Supplementary files
